- Home
- VTVT vs OTLK Comparison
VTVT vs OTLK Comparison
Compare VTVT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- OTLK
- Stock Information
- Founded
- VTVT 2015
- OTLK 2010
- Country
- VTVT United States
- OTLK United States
- Employees
- VTVT N/A
- OTLK N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTVT Health Care
- OTLK Health Care
- Exchange
- VTVT Nasdaq
- OTLK Nasdaq
- Market Cap
- VTVT 56.7M
- OTLK 48.3M
- IPO Year
- VTVT 2015
- OTLK 2016
- Fundamental
- Price
- VTVT $21.94
- OTLK $1.71
- Analyst Decision
- VTVT Strong Buy
- OTLK Strong Buy
- Analyst Count
- VTVT 2
- OTLK 5
- Target Price
- VTVT $35.50
- OTLK $10.20
- AVG Volume (30 Days)
- VTVT 9.3K
- OTLK 390.5K
- Earning Date
- VTVT 05-27-2025
- OTLK 05-23-2025
- Dividend Yield
- VTVT N/A
- OTLK N/A
- EPS Growth
- VTVT N/A
- OTLK N/A
- EPS
- VTVT N/A
- OTLK N/A
- Revenue
- VTVT $1,017,000.00
- OTLK N/A
- Revenue This Year
- VTVT N/A
- OTLK N/A
- Revenue Next Year
- VTVT N/A
- OTLK $288.46
- P/E Ratio
- VTVT N/A
- OTLK N/A
- Revenue Growth
- VTVT N/A
- OTLK N/A
- 52 Week Low
- VTVT $12.12
- OTLK $0.87
- 52 Week High
- VTVT $29.01
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- VTVT 57.22
- OTLK 59.21
- Support Level
- VTVT $20.12
- OTLK $1.35
- Resistance Level
- VTVT $21.52
- OTLK $2.04
- Average True Range (ATR)
- VTVT 1.23
- OTLK 0.13
- MACD
- VTVT -0.09
- OTLK 0.03
- Stochastic Oscillator
- VTVT 67.00
- OTLK 56.92
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.